Key result
Diazoxide cuts fasting insulin ~72% vs placebo in nondiabetic obese men, despite slightly raising glucose.
Why the study?
The optimal dose of diazoxide to promote lipolysis without causing hyperglycemia in nondiabetic obese men was unknown.
Does diazoxide-mediated insulin suppression improve lipid and glucose metabolism in nondiabetic obese men?
RCT
Double-blind
Does diazoxide-mediated insulin suppression improve lipid and glucose metabolism in nondiabetic obese men?
Absolute Event Rate: -72.3% vs -23%
p-value: p=<0.001
In nondiabetic obese men, diazoxide can significantly reduce fasting insulin levels and improve blood pressure and lipid levels, though individualized dose titration is required due to side effects like edema and hyperglycemia.
No takes yet. Share an insight, caveat, or question.
Supports individualized DZX titration for substantial insulin suppression in obese men; extends RCT evidence on metabolic effects with lifestyle intervention.
Loves et al. (2018) conducted an RCT in Obesity in nondiabetic men. Diazoxide vs. Placebo was evaluated on Decrease in fasting insulin levels (p=<0.001). Diazoxide treatment significantly decreased fasting insulin levels compared to placebo (-72.3% vs -23.0%; P<0.001) in nondiabetic obese men, though it caused a small increase in plasma glucose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: